Cho, sung-yup
M.D., Ph.D. / Associate professor
Laboratory of Precision and Molecular Oncology
TEL +82-2-740-8241
FAX 02-744-4534
E-MAIL csybio@snu.ac.kr
WEBSITE https://csybio.wixsite.com/lpmo
Research
Research Field
A. Targeted cancer therapeutics based on cancer genomics, Resistance mechanism of cancer therapeutics, Prediction of responsiveness to cancer immunotherapyB. Our laboratory aims to predict cancer therapeutic responsiveness and develop novel targeted cancer therapeutics based on analysis of cancer genomics, functional genomic experiment using genome-editing technology, molecular mechanism study, analysis of patients’ specimen and tumor mouse model study.
1) Discovery of carcinogenesis and treatment responsiveness-related genes by genome editing-based functional genomic approaches
2) Study in functions and molecular mechanisms of cancer-related genes by molecular and cellular biology approaches
3) Verification of targeted treatment effect and study on mechanism of action using patient-derived xenograft mouse models
Keyword
Cancer genomics, Targeted therapeutics, Drug resistance, Cancer immunotherapy, Patient-derived xenograft modelEducation
- 1994-2000 M.D. Seoul National University College of Medicine, Seoul, Korea
- 2001-2003 M.S. Seoul National University College of Medicine, Seoul, Korea (Biochemistry and Molecular Biology)
- 2003-2010 Ph.D. Seoul National University College of Medicine, Seoul, Korea (Biochemistry and Molecular Biology)
Career
- 2015-2016 Research professor, Department of Life Science, Ewha Womans University, Seoul, Korea
- 2016-2018 Clinical assistant professor, Ewha Institute of Convergence Medicine, Ewha Womans University Mokdong Hospital, Seoul, Korea
- 2018- Associate professor, Department of Biomedical Science, Seoul National University College of Medicine, Seoul, Korea
Publication
- Cho SY et al., Predictive biomarkers for 5-fluorouracil and oxaliplatin-based chemotherapy in gastric cancers via profiling of patient-derived xenografts. Nat Commun. 2021 Aug 10;12(1):4840.
- Jung HR et al., CRISPR screens identify a novel combination treatment targeting BCL-XL and WNT signaling for KRAS/BRAF-mutated colorectal cancers. Oncogene. 2021 May;40(18):3287-3302.
- Cho SY et al., Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice. Nat Microbiol. 2021 Mar;6(3):277-288.
- Cho SY et al., Unstable genome and transcriptome dynamics during tumor metastasis contribute to therapeutic heterogeneity in colorectal cancers. Clin Cancer Res. 2019 May 1;25(9):2821-2834.
- Cho SY et al., Alterations in the Rho pathway contribute to Epstein-Barr virus-induced lymphomagenesis in immunosuppressed environments. Blood. 2018 Apr 26;131(17):1931-1941.
